Roche Gets FDA Approval for Another Label Expansion of Tecentriq
Article excerpt
Highlighted: the sentence this signal was extracted from
Roche RHHBY has secured yet another label expansion for its cancer immunotherapy Tecentriq (atezolizumab) in the United States. The FDA approved Tecentriq and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) in combination with fluoropyrimidine and oxaliplatin chemotherapy for the adjuvant treatment of stage III deficient DNA mismatch repair (dMMR) colon cancer. The approval marks the 12th U.S. indication for Tecentriq and strengthens Roche's oncology portfolio by expanding its reach into an important treatment setting where the risk of cancer recurrence remains high. Year to date, shares of Roche have risen 3.5% compared with the industry 's rise of 11%. Image Source: Zacks Investment Research The FDA decision was based on the phase III ATOMIC study, which enrolled 712 patients with stage III dMMR colon cancer. The trial evaluated the addition of Tecentriq to modified (m) FOLFOX6 chemotherapy (a combination of folinic acid, fluorouracil, and oxaliplatin) in patients with stage III colon cancer who have a deficiency in DNA mismatch repair. The study demonstrated that adding Tecentriq reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone. The 36-month disease-free survival rate was 86% for patients receiving Tecentriq plus chemotherapy, compared with 76% for those receiving chemotherapy alone. The safety profile was consistent with...
Keep reading with a free account
The rest of this article, and every signal for Roche, is in your free account.
